Cargando…
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Unprecedented successes regarding cancer immunotherapy have been achieved, in which therapeutic agents are used to target immune cells rather than cancer cells. The most effective immunotherapy to date is the group of immune checkpoint inhibitors (CPI), targeting, for example, cytotoxic T-lymphocyte...
Autores principales: | Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B. A. G., Blank, Christian U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677983/ https://www.ncbi.nlm.nih.gov/pubmed/31423333 http://dx.doi.org/10.1136/esmoopen-2018-000472 |
Ejemplares similares
-
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Michailidou, Despina, et al.
Publicado: (2021) -
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023) -
Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019) -
Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019) -
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)